Latest Regulatory Updates News

Fiducian Group Limited has reported a robust 23% increase in net profit after tax for the year ended June 2025, driven by strong inflows and resilient performance across its financial planning, platform administration, and investment management segments despite challenging market conditions.

Vanguard Investments Australia has announced the estimated distribution and tax components for its Vanguard FTSE Asia ex Japan Shares Index ETF for the quarter ending September 2025, highlighting key details for investors on cash payouts and tax implications.

The European Medicines Agency has approved continuous bi-monthly dosing of CLINUVEL’s SCENESSE® for adult erythropoietic protoporphyria patients, removing previous annual dose limits and aligning Europe with US treatment standards.

VGI Partners Global Investments has completed its on-market share purchases under the Dividend Reinvestment Plan, updating investors with a new Appendix 3A.1 filing.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.

Nyrada Inc has responded to ASX inquiries confirming the timely and compliant disclosure of positive safety data from its Phase I clinical trial of Xolatryp. The company detailed the timeline of its awareness and release of information, affirming adherence to continuous disclosure rules.

Life360, Inc. reported a return to profitability in Q2 2025, driven by strong subscription growth and strategic partnerships, while also announcing a leadership transition and issuing $320 million in convertible notes.

AVITA Medical has filed its Q2 2025 Form 10-Q, reaffirming its leadership in acute wound care with its FDA-approved RECELL System and expanding international footprint.

DMC Mining Limited has extended the closing date of its public share offer to mid-September due to delays in securing exploration licences for key projects in Guinea. The company plans further regulatory updates as it awaits final approvals.

Nyrada Inc. has raised $8.25 million through a strategic placement to fund its upcoming Phase IIa clinical trial of Xolatryp for acute myocardial infarction, positioning the company for a pivotal year ahead.

Prescient Therapeutics has raised nearly $10 million through a placement and share purchase plan to advance its promising PTX-100 targeted cancer therapy into pivotal clinical stages.

Atlas Arteria reported a robust 10.7% increase in Q2 2025 toll revenue, driven by strong traffic growth and toll hikes, while the French government reaffirmed its backing of the concession model with regulatory updates expected later this year.